Rodríguez Baisi K, Tollefson M
Ponce Health Sciences University, Ponce, Puerto Rico.
Mayo Clinic, Department of Dermatology, Rochester, Minnesota, USA.
Drugs Today (Barc). 2020 Aug;56(8):515-530. doi: 10.1358/dot.2020.56.8.3168447.
There is a need for new and effective topical treatment options for psoriasis. Recent phase I and II clinical trials have demonstrated efficacy of the novel nonsteroidal drug tapinarof to treat mild to moderate plaque psoriasis. Tapinarof is an aryl hydrocarbon receptor (AHR) agonist that induces antioxidant, immunomodulatory and epidermal differentiation regulation pathways. In this review, we examine the current preclinical and clinical studies with a focus on the mechanism of action, pharmacokinetics, safety and efficacy of tapinarof to treat psoriasis.
对于银屑病，需要新的有效局部治疗方案。近期的I期和II期临床试验已证明新型非甾体药物他扎罗夫治疗轻至中度斑块状银屑病的疗效。他扎罗夫是一种芳烃受体（AHR）激动剂，可诱导抗氧化、免疫调节和表皮分化调节途径。在本综述中，我们重点研究了目前关于他扎罗夫治疗银屑病的作用机制、药代动力学、安全性和疗效的临床前和临床研究。
